Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orvacabtagene autoleucel - Juno Therapeutics

Next Previous
X
Search
Drug Profile

Orvacabtagene autoleucel - Juno Therapeutics

Alternative Names: Anti BCMA CAR T cell therapy - Juno Therapeutics; Anti-BCMA CAR - Juno Therapeutics; Anti-BMCA Chimeric antigen receptor cell therapy-Juno Therapeutics; BCMA-CAR-T-Juno Therapeutics; BCMA-specific CAR expressing T-Lymphocytes-Juno Therapeutics; BCMA-specific CAR-T-Juno Therapeutics; BCMA-Targeted CAR-T Cells-Juno Therapeutics; JCARH-125; orva-cel

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 04 Jun 2021 Updated efficacy and adverse events data from the phase I/II EVOLVE trial in Multiple myeloma presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 29 May 2020 Efficacy and adverse events data from the phase I/II EVOLVE trial in Multiple myeloma presented at 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 03 Dec 2018 Interim adverse events and efficacy data from phase I/II Evolve trial in Multiple myeloma presented at the 60th American Society of Hematology Annual Meeting (ASH-Hem-2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top